Study #2020-0279
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post– PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who H
MD Anderson Study Status
Not Accepting
Treatment Agent
KRT-232, Ruxolitinib
Description
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in combination with ruxolitinib.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelofibrosis
Study phase:
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.